Key Points
- ICON Chief Accounting Officer Emer Lyons sold 272 shares at an average price of $182.37, worth $49,604.64. The sale reduced Lyons’ direct holdings by 21.55% and was made to cover tax obligations tied to vested equity awards.
- ICON shares opened at $183.78, with a $14.07 billion market capitalization and a 52-week range of $66.57 to $203.91. The company recently exceeded quarterly expectations, reporting $2.56 in EPS and $2.06 billion in revenue.
- Analysts have a consensus “Hold” rating and an average price target of $174.73, below the reported share price. Institutional investors own approximately 95.61% of ICON’s stock.
Icon Plc (NASDAQ:ICLR - Get Free Report) CAO Emer Lyons sold 272 shares of Icon stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $182.37, for a total value of $49,604.64. Following the transaction, the chief accounting officer directly owned 990 shares in the company, valued at approximately $180,546.30. This trade represents a 21.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Icon Price Performance
Shares of ICLR opened at $183.78 on Tuesday. The company has a market capitalization of $14.07 billion, a price-to-earnings ratio of 43.14, a P/E/G ratio of 11.98 and a beta of 1.24. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. The business's 50-day moving average is $169.15 and its 200-day moving average is $146.16.
Icon (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm's revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.26 earnings per share. Equities research analysts expect that Icon Plc will post 9.55 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have weighed in on ICLR. Robert W. Baird set a $194.00 price objective on shares of Icon in a research note on Friday, July 31st. Zacks Research raised shares of Icon from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. UBS Group began coverage on shares of Icon in a report on Wednesday, September 30th. They set a "neutral" rating and a $195.00 price target on the stock. Bank of America raised shares of Icon from an "underperform" rating to a "neutral" rating and set a $185.00 price target on the stock in a research note on Friday, October 9th. Finally, William Blair raised shares of Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Icon currently has a consensus rating of "Hold" and a consensus target price of $174.73.
View Our Latest Analysis on ICLR
Institutional Investors Weigh In On Icon
Large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company's stock valued at $68,000 after buying an additional 69 shares during the last quarter. Grove Bank & Trust grew its holdings in Icon by 30.0% during the 2nd quarter. Grove Bank & Trust now owns 866 shares of the medical research company's stock worth $150,000 after acquiring an additional 200 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in Icon by 120.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company's stock worth $107,000 after acquiring an additional 336 shares during the last quarter. Westpac Banking Corp increased its position in Icon by 35.0% in the 1st quarter. Westpac Banking Corp now owns 1,547 shares of the medical research company's stock valued at $171,000 after acquiring an additional 401 shares in the last quarter. Finally, First Trust Advisors LP increased its position in Icon by 17.0% in the 1st quarter. First Trust Advisors LP now owns 2,760 shares of the medical research company's stock valued at $305,000 after acquiring an additional 401 shares in the last quarter. Institutional investors own 95.61% of the company's stock.
About Icon
(
Get Free Report)
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
